Abstract: Anti-adrenergic therapy has been widely accepted as an important therapeutic intervention in patients with chronic heart failure. However, there has been continuing controversy regarding the risks and clinical signifi cance of metabolic effects of different anti-adrenergic drugs. This review summarizes what has been learned from clinical trial evidence regarding the benefi ts of anti-adrenergic drugs in diabetic patients with chronic heart failure.
Introduction
It has been increasingly recognized that diabetes mellitus is an important vascular disease in patients with heart failure and cardiomyopathy. Glucose abnormalities in patients with heart failure are common, under-diagnosed, and often associated with worsening symptomatic status and poor clinical outcomes (Tang and Young 2001) . In the RESOLVD (Randomized Evaluation of Strategies of Left Ventricular Dysfunction) substudy, up to 43% of patients with left ventricular systolic dysfunction had documented glucose abnormalities that were often previously undiagnosed (Suskin et al 2000) . This is in part related to the impaired glucose metabolism associated with enhanced sympathetic drive and worsening insulin resistance that is part of the pathophysiology of heart failure (Opie 2004) .
Diabetes can cause myocyte hypertrophy, interstitial fi brosis, impaired myocardial blood fl ow, and increased turnover of free fatty acids, all leading to the development of cardiomyopathy and heart failure (Tang and Young 2001) . Clinical studies have now confi rmed that patients with heart failure have up to a 4 times higher risk of developing diabetes mellitus (Kannel and McGee 1979) , and the incidence of diabetes in patients with established heart failure has increased over previous decades (From et al 2006) . Furthermore, the risk of hospitalizations for heart failure is greatly amplifi ed in the patients with diabetes mellitus (Deedwania et al 2005) .
The mechanism and consequence of insulin resistance in dysfunctional myocardium is currently unknown, but an increasing body of evidence has emerged concerning the relationship between heightened sympathetic activation and the development of myocardial and peripheral insulin resistance (Parsonage et al 2002) . In animal studies of advanced heart failure, myocardial insulin resistance is evident in the setting of increased sympathetic nervous system activation and oxidative stress, directly leading to lipolysis, subsequent alteration in the insulin-signaling cascade, and myocyte dysfunction (Nikolaidis et al 2004) . In small single-center studies, insulin resistance has been linked to systolic heart failure in patients without underlying diabetes mellitus. In particular, patients with heart failure have greater impairment in insulin sensitivity compared with matched controls (Swan et al 1997; Witteles et al 2004) .
Effects of anti-adrenergic therapy on glucose metabolism
Glycemic control has been the primary therapeutic target for treating patients with diabetes mellitus, even in the setting of heart failure (Tang 2006) . In the Kaiser registry, increasing glycosylated hemoglobin levels portends a higher incidence of subsequent heart failure (Iribarren et al 2001) , an observation that affi rms data from the United Kingdom Prospective Diabetes Study (UKPDS) (Stratton et al 2000) . Even in the population without diabetes mellitus, elevated fasting plasma glucose or glycosylated hemoglobin levels have been associated with poorer long-term outcomes in both acute and chronic heart failure settings (Bhatia et al 2004; Gerstein et al 2005) .
Treatment with anti-adrenergic drugs may increase peripheral vascular resistance, impairing peripheral blood fl ow leading to impaired glucose disposal to skeletal muscles. These effects are likely to be amplifi ed in the setting of cardiac insuffi ciency, where vascular changes and neurohormonal upregulation occur as a compensatory response. Furthermore, blocking the sympathetic beta-stimulation of hepatic glucose production and blunting the symptoms of hypoglycemia (such as tachycardia) worsening metabolic control may have theoretical adverse consequences.
Clinical studies suggest that various anti-adrenergic drugs may carry differential effects on insulin sensitivity (Figure 1) . One of the earliest investigations compared carvedilol (beta-1, beta-2, and alpha-1 selective) with metoprolol tartrate (beta-1 selective) in diabetic hypertensive subjects. Patients with non-insulin-dependent diabetes mellitus received either carvedilol (25 mg twice daily) or metoprolol tartrate (50 mg twice daily) for a period of 4 weeks and up-titrated as needed. After 4 weeks of carvedilol treatment, 23 of 25 patients (92%) showed a good response to therapy (reduction of diastolic blood pressure below 90 mmHg). Doubling of dosage in the carvedilol group did not further increase the response rate after another one month of treatment. In contrast, the response rate after 4 and 8 weeks of metoprolol treatment was 79% and 83%, respectively (Ehmer et al 1988) . In both treatment groups, blood glucose concentrations and glycosylated hemoglobin were maintained within narrow limits. Subsequently, the differential effects were demonstrated in a 12-week isoglycemic hyperinsulinemic glucose clamp experiment (the gold standard for assessing insulin sensitivity) in patients with essential hypertension, whereby insulin sensitivity decreased signifi cantly by approximately 14% after metoprolol tartrate but increased after carvedilol (Jacob et al 1996) . Furthermore, a decrease in high-density lipoprotein cholesterol and an increase in triglycerides levels were observed in patients in the metoprolol-treated group, whereas these parameters remained unchanged in patients in the carvedilol-treated group. The explanation of this difference was the compensatory effects of alpha-1 adrenergic blockade in carvedilol that lead to vasodilatation, improved oxygen delivery, and reduced insulin release. There is also blockade of beta-2 adrenergic stimulation, leading to suppressed substrate preference for non-esterifi ed fatty acid and enhanced insulin signaling. Similar effects are also seen in the post-infarction setting (Basat et al 2006) , suggesting that cardioselectivity of anti-adrenergic therapy may play a role in infl uencing the metabolic profi le.
Specifi cally in the setting of heart failure in patients without overt diabetes, treatment with carvedilol can lead to a signifi cant decrease in fasting insulinemia as well as infl ammation (Hara et al 2003) , and subsequent improvement or unaltered insulin sensitivity (Refsgaard et al 2002; Ferrua et al 2005) . In animal models, both carvedilol and metoprolol succinate had comparable heart rate effects, but carvedilol-treated dogs with pace-induced heart failure showed signifi cantly greater increases in stroke volume and cardiac output and decreases in left ventricular end-diastolic pressure and systemic vascular resistance (Nikolaidis et al 2006) . Furthermore, carvedilol may increase myocardial glucose uptake, and may blunt actions of norepinephrine and glucagon. These effects clearly illustrate the metabolic benefi ts of a non-selective adrenergic blockade by carvedilol.
The GEMINI (Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives) trial constituted a milestone in the long-standing debate regarding the differential metabolic effects of different anti-adrenergic drugs. The GEMINI study randomized 1235 hypertensive patients with non-insulin-dependent type 2 diabetes mellitus in a 2-to-1 fashion to receive either metoprolol tartrate or carvedilol in addition to baseline angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and stable anti-diabetic regimens. After 5 months of follow-up, the blood pressure effects between the two antiadrenergic drugs were comparable. However, an increase in glycosylated hemoglobin of 0.15% was observed in the metoprolol tartrate arm, whereas an increase in glycosylated hemoglobin of 0.02% was observed in the carvedilol arm (Bakris et al 2004) . The separation occurred as early as Month 2 of therapy and continued to diverge. Insulin resistance (estimated by homeostatic model assessment or HOMA-IR) and microalbuminuria (estimated by urinary albumin/creatinine ratio) were also signifi cantly reduced in the carvedilol arm compared with the metoprolol tartrate arm. Interestingly, weight gain and bradycardia occurred more frequently, and there were more apparent increases in triglyceride levels and development of microalbuminuria in the metoprolol tartrate arm. Changes in low-density as well as high-density lipoprotein cholesterol levels were similar between the two groups, although only a small percentage of patients were treated with statin therapy. These data confi rmed different metabolic effects among different anti-adrenergic drugs, although the results still do not specify the underlying mechanisms. Furthermore, there were no long-term outcome data to illustrate the clinical consequences of these differences in metabolic effects, and the fi ndings can only be applied to the heart failure population by extrapolation.
The role of anti-oxidant properties of anti-adrenergic drugs is less clear. Oxidative stress has been implicated in the pathophysiology of heart failure, although the mechanisms are complex. In both heart failure and type 2 diabetes mellitus, reactive oxygen species are increased and endothelial nitric oxide synthase is diminished. By reducing nitric oxide availability, nitric-oxide derived vasodilatation is reduced, which can lead to endothelial dysfunction and poor long-term mortality in heart failure (Katz et al 2005) . There has been evidence to suggest that the transcardiac gradient of plasma oxidized low-density lipoprotein is signifi cantly lower in patients who receive carvedilol compared with those who do not (Tsutamoto et al 2001) . Therefore, the possibility of carvedilol as a scavenger of oxidative free radicals, a chelator of metal ions, and its ability to improve insulin sensitivity through reduction of oxidative stress in patients with diabetes mellitus is encouraging, although such relationships have yet to be confi rmed in the human heart failure population (Giugliano et al 1997) .
Anti-adrenergic therapy in patients with heart failure and diabetes mellitus
Patients with diabetes mellitus have been included in the majority of large-scale clinical trials in chronic heart failure; therefore data have emerged regarding the benefi ts versus risks of anti-adrenergic therapy in this population through post-hoc analyses. There have been several limitations, however, to this work. First, subgroup analyses (even when pre-specifi ed) are often underpowered and potentially biased, in part because diabetes mellitus status has not been used as a variable for stratifi ed randomization. Furthermore, diabetes mellitus is often documented as a Tang dichotomous variable. Therefore, the mere presence of a diagnosis of diabetes mellitus cannot provide insight into the degrees of glycemic control and vascular abnormalities of the patient.
One of the fi rst published papers in this topic was the subgroup analysis from the Second Cardiac Insuffi ciency Bisoprolol Study (CIBIS-II) with the use of bisoprolol. The relative risk of bisoprolol versus placebo for mortality was 0.81 (19% reduction, 95% confi dence interval [CI] 0.51-1.28) in patients with diabetes mellitus, compared with 0.66 (95% CI of 0.54-0.81) in patients without diabetes mellitus (Erdmann et al 2001) . These results may have been affected by the relatively small sample size of subjects with diabetes mellitus in CIBIS-II (only 12% of the study population). Meanwhile in the MERIT-HF trial, a larger proportion of subjects (n = 985, or 25%) presented with a diagnosis of diabetes mellitus, among whom 199 had severe heart failure (NYHA III-IV, LVEF Ͻ25%) (Deedwania et al 2005) . A pre-specifi ed subgroup analysis in the cohort of patients with diabetes mellitus demonstrated a mortality reduction following treatment with metoprolol succinate when compared with placebo (10.1% vs 12.7%, or an 18% reduction). This compares with a 31% mortality reduction in the non-diabetes subgroup (Deedwania et al 2005) . Nevertheless, the risk of hospitalization for heart failure was reduced by 37% with metoprolol succinate in the MERIT-HF trial. One very reassuring point from this report was the lack of signifi cant adverse effects of metoprolol succinate compared with placebo in patients with diabetes mellitus, even in those with severe heart failure.
The largest experience of anti-adrenergic therapy use in patients with chronic heart failure and diabetes mellitus has been with the use of carvedilol. Benefi cial effects of carvedilol have been seen across the spectrum of heart failure trials, irrespective of the presence or absence of diabetes mellitus. A recent meta-analysis summarized this clinical trial experience with several of the landmark carvedilol heart failure studies looking at patients with diabetes mellitus. Among a total of 1411 subjects with diabetes mellitus enrolled in 7 studies (25% of all enrollees), carvedilol demonstrated a statistically signifi cant survival benefi t (34% risk reduction, Figure 2 ) (Bell et al 2006) , even after adjustment for age, left ventricular ejection fraction, ischemic etiology, diabetes history, and weight. The authors claimed that the number of patients needed to treat with carvedilol for 1 year to prevent 1 death was 23 for the overall population, and 25 for patients with diabetes mellitus. These estimates are still more favorable than that from SOLVD (estimated number needed to treat with enalapril being 78 for 1 year to prevent 1 death) (Dries et al 2001) .
The latest data came from BEST (Beta-blocker Evaluation of Survival Trial), a database of 2708 patients with advanced heart failure (36% with diabetes mellitus) randomized to bucindolol versus placebo (Domanski et al 2003) . While in the overall trial bucindolol did not demonstrate a signifi cant survival benefi t, the use of bucindolol was associated with a signifi cant benefi t compared with placebo in subjects with diabetes mellitus when death plus heart failure hospitalizations were combined as endpoints.
Combining the experience of the landmark anti-adrenergic therapy clinical trials, several meta-analyses have been conducted to determine whether there are differences in mortality and morbidity benefi ts with different anti-adrenergic drugs. All analyses found that patients with chronic heart failure and diabetes mellitus had higher event rates compared to those without diabetes (Haas et al 2003; Shekelle et al 2003; Deedwania et al 2005) . In the pooled analysis by Shekelle and colleagues, anti-adrenergic therapy use was associated with a 23% mortality reduction in patients with diabetes mellitus versus a 35% mortality reduction in those without diabetes mellitus (Shekelle et al 2003) . This fi nding was consistent with a larger meta-analysis, which concluded that anti-adrenergic therapy for heart failure was benefi cial in patients with diabetes mellitus (relative risk of 0.84; 95% CI 0.73-0.96; p = 0.01, see Figure 2 ) (Haas et al 2003) .
Unanswered questions
It is important to emphasize that while carvedilol appears to have favorable metabolic effects over metoprolol or bisoprolol, all three approved anti-adrenergic drugs can be used effectively in the setting of diabetes mellitus. Indeed, there is only inferred evidence but no prospective data to support the switch from stable regimens of metoprolol succinate or bisoprolol to carvedilol in patients with heart failure and diabetes mellitus at present. The incremental long-term clinical benefi t of carvedilol in this population over other currently approved anti-adrenergic drugs is still debated. In particular, several unanswered questions remain despite the wide range of studies that have emerged over the years as well as the extensive use of carvedilol, bisoprolol, and metoprolol succinate in the clinical setting.
First, what is the impact of the differential metabolic effects of anti-adrenergic drugs on long-term outcomes in the clinical heart failure setting? If the underlying pathophysiology of heightened risk of developing diabetes in the heart failure population is the presence of overactive sympathetic drive (which is counteracted by any anti-adrenergic drug), the differences among anti-adrenergic drugs on long-term outcomes should be minimal. The carvedilol investigators have argued that a consistent 35% reduction has been observed in both diabetic and non-diabetic subgroups of patients with heart failure, particularly in the COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival) study (Mohacsi et al 2001; Bell et al 2006) . They further use the results of COMET (Carvedilol or Metoprolol Evaluation Trial) to justify their argument, stating that the head-to-head comparison in COMET showed a 17% mortality reduction, a 25% relative reduction in vascular events (stroke or myocardial infarction), and a 12% relative reduction in the development of new-onset diabetes mellitus with longterm treatment using carvedilol over metoprolol tartrate in patients with chronic heart failure (Poole-Wilson et al 2003; Torp-Pedersen et al 2007; Remme et al 2007) . However, the MERIT-HF investigators responded by demonstrating a non-signifi cant statistical test for treatment interaction in their own post-hoc meta-analysis between CIBIS-II, MERIT-HF, and COPERNICUS (Deedwania et al 2005) .
Second, are there specifi c subgroups of patients with diabetes mellitus that may limit the effectiveness and potentiate adverse effects of anti-adrenergic drugs? In other words, are there any noticeable differences between insulin-dependent versus non-insulin-dependent diabetes mellitus regarding the benefi ts and risks of anti-adrenergic drugs in the heart failure setting? What is clear from the clinical trial experiences is that irrespective of the type of anti-adrenergic drugs used, patients with diabetes compared with those without diabetes had signifi cantly greater weight gain, hyperglycemia, hypoglycemia, elevated creatinine levels, syncope, myocardial infarction, and cerebrovascular accidents when treated with anti-adrenergic therapy. The results from GEMINI and many other small mechanistic studies have confi rmed the potential differences in metabolic consequences between anti-adrenergic drugs. Hence, there may be theoretical advantages in using carvedilol in patients with brittle diabetes or with evidence of vascular compromise (such as microalbuminuria).
The United States Food and Drug Administration (FDA) has recently added warnings to the label of anti-adrenergic drugs (such as carvedilol) regarding their use in patients with heart failure and diabetes mellitus. The FDA stated that patients subject to spontaneous hypoglycemia and patients with diabetes mellitus receiving insulin/oral hypoglycemic drugs should be warned of the possibility that anti-adrenergic therapy may mask manifestations of hypoglycemia (particularly tachycardia), potentiate insulin-induced hypoglycemia, and possibly delay recovery of serum glucose levels. Therefore, close monitoring of blood glucose levels is advised on initiation, adjustment, or discontinuation of any anti-adrenergic therapy in patients with diabetes mellitus.
Conclusion
Patients with chronic heart failure and diabetes mellitus should be treated with anti-adrenergic therapy because of its consistent mortality benefi ts observed in pivotal trials. The differential metabolic effects of carvedilol over other anti-adrenergic therapies have largely been implicated by logical deduction from experimental heart failure models as well as data from two head-to-head clinical trials. Regardless of which anti-adrenergic drug is being used to treat chronic heart failure, careful monitoring of glycemic parameters and adverse effects remains important, particularly in the presence of diabetes mellitus.
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